Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Yulia Lyuboslavsky

Clinical Nurse Specialist, Adult Health Austin, TX Clinical Nurse Specialist

NPI 1215254024 CMS profile 10823310

4310 James Casey St, Austin, TX 78745

Open in the dashboard

General payments

$36,141

664 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yulia Lyuboslavsky of Austin, TX is reported in the CMS Open Payments database as having received $36,141 across 664 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Clinical Nurse Specialist, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,206 106
2024 General $4,096 109
2023 General $5,958 125
2022 General $9,239 138
2021 General $10,641 186

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yulia Lyuboslavsky
  • Clinical Nurse Specialist, Adult Health median
  • Middle half of Clinical Nurse Specialist, Adult Health
  • National median

In program year 2025, general payments to Yulia Lyuboslavsky were reported at $6,206. Among 446 Clinical Nurse Specialist, Adult Health profiles paid that year, the median was $193 and the middle half received between $61 and $597.

Show as a table
Year Yulia Lyuboslavsky Clinical Nurse Specialist, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $10,641 $133 $48–$445 $132
2022 $9,239 $163 $57–$526 $149
2023 $5,958 $173 $64–$597 $160
2024 $4,096 $171 $54–$575 $164
2025 $6,206 $193 $61–$597 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $29,255 271 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $2,117 189 payments
  3. Janssen Biotech, Inc. $541 23 payments
  4. Celgene Corporation $365 20 payments
  5. Janssen Scientific Affairs, LLC $354 3 payments
  6. Novo Nordisk Inc $313 4 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $287 13 payments
  8. Medtronic, Inc. $265 3 payments
  9. Ardelyx, Inc. $262 13 payments
  10. Nestle HealthCare Nutrition Inc. $244 15 payments
  11. Other $2,137 110 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $22,050 24 payments
  2. Food and Beverage $11,862 607 payments
  3. Travel and Lodging $2,113 30 payments
  4. Education $115 3 payments
Products named General payments · program years 2021–2025
  1. MAVYRET $27,501 171 payments
  2. XIFAXAN $1,757 160 payments
  3. TREMFYA $656 12 payments
  4. RINVOQ $651 43 payments
  5. STELARA $595 17 payments
  6. CREON $451 25 payments
  7. LINZESS $420 27 payments
  8. SKYRIZI $371 7 payments
  9. ZEPOSIA $365 20 payments
  10. TRULANCE $359 29 payments
  11. Other $4,093 198 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

713

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$130,385

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

34.8%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 14 $34,569
Xifaxan Rifaximin Brand 12 $34,535
Linzess Linaclotide Brand 35 $25,214
Trulance Plecanatide Brand 16 $11,782
Plenvu Peg3350/Sod Sul/Nacl/Kcl/Asb/C Brand 53 $7,165
Mesalamine Er Mesalamine Brand 15 $4,887
Rabeprazole Sodium Generic 60 $1,954
Lubiprostone Generic 17 $1,584
Pantoprazole Sodium Generic 130 $1,545
Suflave Peg 3350/Sod Sulf,chlr/Pot/Mag Brand 11 $1,347

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$18,300

Medicare's payments for the services billed

Medicare patients

226

Average age 74

Services billed

255

134 women, 92 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 37%
Diabetes 25%
Depression 25%
Osteoporosis 19%
Chronic kidney disease 16%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MAVYRET
  • AbbVie, Inc. $2,269
$2,269 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $251
$251 12 —
SKYRIZI
  • AbbVie, Inc. $211
$211 — —
TREMFYA
  • Janssen Scientific Affairs, LLC $101
  • Janssen Biotech, Inc. $70
$171 — —
RINVOQ
  • AbbVie, Inc. $165
$165 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

664 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Adult Health in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record